Abstract
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, durvalumab remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation. In addition, a study assesses a fixed‐duration combination regimen of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia, and multitargeted therapy is safe and leads to durable remission of diffuse large B‐cell lymphoma.